Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication BETOPTIC S ® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. BETOPTIC S is a beta-adrenergic receptor inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. ( 1 ) FDA label
Also known as BETOPTIC S (betaxolol HCl)
BETOPTIC S · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Betaxolol | EXPERIMENTAL | Two doses daily for 12 weeks |
| TGFS 0.25% | EXPERIMENTAL | Two doses daily for 12 weeks |
| TGFS 0.5% | EXPERIMENTAL | Two doses daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| BETOPTIC S (betaxolol HCl) | DRUG | betaxolol HC) |
| Timolol Gel-forming Solution (TGFS) | DRUG | timolol maleate 0.25% and 0.5% |
INCLUSION: * Children 5 years old and younger * require treatment for glaucoma or ocular hypertension * whose vision is 20/80 or better * have a cup-to-disc ratio of 0.8 or less EXCLUSION: * do not have abnormal fixation * IOP greater than 36 mm Hg * significant retinal disease * penetrating kera...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
BETOPTIC S is used to treat glaucoma and ocular hypertension, conditions in which elevated pressure inside the eye can damage the optic nerve. It is an ophthalmic solution developed by Alcon Inc. (ticker ALC) and was studied in pediatric patients as young as one week old with glaucoma or ocular hypertension.
BETOPTIC S is made by Alcon Inc., which trades under the ticker ALC. Alcon is an eye care company, and BETOPTIC S is part of its ophthalmology portfolio. The drug was evaluated in a company-sponsored Phase 3 trial conducted in the United States.
BETOPTIC S has been studied in Phase 3 clinical development for glaucoma and ocular hypertension. One Phase 3 trial has been completed, and no trials are currently listed as active. The completed study was randomized, double-blind, and controlled, enrolling 105 pediatric patients.
BETOPTIC S was evaluated in the Phase 3 trial NCT00061542, titled a safety and efficacy study of BETOPTIC S 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric patients with glaucoma or ocular hypertension. The trial enrolled 105 participants in the United States and is completed.
Yes, BETOPTIC S is also known as BETOPTIC S (betaxolol HCl). Betaxolol HCl is the active ingredient in the ophthalmic solution. Readers searching for either name are looking at the same Alcon Inc. product studied for glaucoma and ocular hypertension.